Exploring JCA Timelines: Opportunities and Challenges for Pharma and Biotech In the evolving landscape of EU healthcare, the introduction of Joint Clinical Assessments (JCA) as part of the new Health Technology Assessment (HTA) regulations signifies a pivotal shift. These assessments are redefining Pharma and Biotech companies' approach to product evaluation and approval, presenting both significant [...]